Bringing Clinical Trials to Life

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….
More...

Dermatology

Together, Cu-Tech and Synteract create the leading dermatology CRO, with global capabilities and unparalleled access to sites and patients. Our focus on novel and required dermatology drugs provides dedicated research services unmatched in the market.
More...

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends leading towards new treatments…
More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…
More...

Rare & Orphan Diseases

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…
More...

11/27/2018 - 11/29/2018 : Dermatology Drug Development Summit More...

11/15/2018: Synteract has acquired KinderPharm, a specialty pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. More ...

11/20/2018: 5 Reasons to Work with Synteract For Your Pediatric Clinical Trial - Whether you are looking for small scale support, assistance with a specific service, or complete study design and management, Synteract draws on extensive, end-to-end experience in helping clients efficiently navigate the complexities of pediatric trials and regulatory environments.

Synteract Blog 

11/20/2018: At Synteract we understand that rare and orphan indications typically come with unique characteristics and can help guide you through the most demanding and challenging indications. Discover how we can partner with you to develop the best strategies for your rare and #orphandisease study: http://ow.ly/GUDM50jKaHj

Synteract on LinkedIn

11/19/2018: In addition to enhancing our pediatric center of development, the acquisition of KinderPharm enables us to become y… https://t.co/mk0SRTCe5X

Synteract Twitter Feed
x

Contact Synteract

Tell us how to stay in touch with you:

*Required